Literature DB >> 17235309

Evidence for intercellular trafficking of VP22 in living cells.

Marie-Luise Lemken1, Claudia Wolf, Wolfgang A Wybranietz, Ulrike Schmidt, Irina Smirnow, Hans-Joerg Bühring, Andreas F Mack, Ulrich M Lauer, Michael Bitzer.   

Abstract

The intercellular trafficking property of the herpes simplex virus type 1 tegument protein VP22 makes it a promising tool for overcoming low transduction efficiencies in gene therapy. However, recent reports suggest not only that VP22 cannot facilitate intercellular spreading and that trafficking of VP22 fusion proteins results from artifacts of cell fixation only. To provide direct evidence for the presence or absence of VP22-mediated intercellular trafficking, we generated an adenoviral vector with a dual expression cassette for VP22 fused to green fluorescent protein (VP22 GFP) and DsRed under the control of distinct human cytomegalovirus immediate-early enhancer/promoter regions. Using this vector, we were able to distinguish clearly between primary transduced cells and cells taking up VP22GFP by intercellular trafficking. To our knowledge, for the first time, we could demonstrate by live-cell confocal fluorescence microscopy that VP22GFP can be found intracellularly in unfixed recipient cells. The extent of VP22 spread was similar in paraformaldehyde-fixed cells and unfixed cells as demonstrated by fluorescence-activated cell sorting analysis. We thus confirmed the ability of VP22-mediated intercellular trafficking in live unfixed cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235309     DOI: 10.1038/sj.mt.6300013

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

1.  Replication-competent herpes simplex virus 1 isolates selected from cells transfected with a bacterial artificial chromosome DNA lacking only the UL49 gene vary with respect to the defect in the UL41 gene encoding host shutoff RNase.

Authors:  Maria Teresa Sciortino; Brunella Taddeo; Maria Giuffrè-Cuculletto; Maria Antonietta Medici; Antonio Mastino; Bernard Roizman
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  Abrogation of microsatellite-instable tumors using a highly selective suicide gene/prodrug combination.

Authors:  Cristina Ferrás; Joachim A F Oude Vrielink; Johan W A Verspuy; Hein te Riele; Anastasia Tsaalbi-Shtylik; Niels de Wind
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

3.  Induction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion protein to tumors in mice.

Authors:  Makiya Nishikawa; Takayuki Otsuki; Atsushi Ota; Xin Guan; Seiji Takemoto; Yuki Takahashi; Yoshinobu Takakura
Journal:  Mol Ther       Date:  2009-09-01       Impact factor: 11.454

Review 4.  Alphaherpesviruses and the cytoskeleton in neuronal infections.

Authors:  Sofia V Zaichick; Kevin P Bohannon; Gregory A Smith
Journal:  Viruses       Date:  2011-06-27       Impact factor: 5.048

5.  Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain.

Authors:  A V Kalra; R B Campbell
Journal:  Br J Cancer       Date:  2007-10-02       Impact factor: 7.640

6.  The study of the intercellular trafficking of the fusion proteins of herpes simplex virus protein VP22.

Authors:  Xiaodong Xue; Jianhua Huang; Huishan Wang
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

7.  Mechanisms of immunization against cancer using chimeric antigens.

Authors:  Manuel E Engelhorn; José A Guevara-Patiño; Taha Merghoub; Cailian Liu; Cristina R Ferrone; Gabriele A Rizzuto; Daniel H Cymerman; David N Posnett; Alan N Houghton; Jedd D Wolchok
Journal:  Mol Ther       Date:  2008-02-26       Impact factor: 12.910

8.  VP22 herpes simplex virus protein can transduce proteins into stem cells.

Authors:  I Gabanyi; F H Lojudice; P M Kossugue; E Rebelato; M A Demasi; M C Sogayar
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.